Prosecution Insights
Prosecution Insights
10 pending office actions • 9 clients • 9 examiners • 8 art units • 0 of 10 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (30%) |
| §103 only | 2 (20%) |
| §112 only | 3 (30%) |
| Multi-statute (no §101) | 2 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 2 | 42.6% | +38.0% |
| NESTOR, DONNA MICHELLE | 1 | 57.7% | +43.7% |
| PERSONS, JENNA L | 1 | 50.0% | +60.0% |
| BAEK, JONGHWAN NMN | 1 | 75.0% | +0.0% |
| HAM, JIEUN | 1 | 50.0% | +62.5% |
| BALLARD, KIMBERLY | 1 | 53.9% | +48.0% |
| SPAINE, ROBERT FRANKLIN | 1 | 100.0% | +0.0% |
| LU, CHENG | 1 | 53.7% | +66.2% |
| COUNTS, GARY W | 1 | 59.1% | +29.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17821291 | IMMUNOMODULATORY PROTEIN FOR PREVENTION OF CORONAVIRUS INFECTION | SPAINE, ROBERT FRANKLIN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253576 | ACTIVE CANCER IMMUNOTHERAPY BY IMMUNE MODULATION VIA GLOBO SERIES ANTIGENS | HAM, JIEUN | 28d overdue |
| 17595830 | COMPANION DIAGNOSTIC ASSAY FOR GLOBO-H RELATED CANCER THERAPY | COUNTS, GARY W | 11d overdue |
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | SALMON, KATHERINE D | 9d |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | — |
| 17756022 | USE OF ANTI-EPCAM ANTIBODIES IN CANCER THERAPY | LU, CHENG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18747694 | CELLS FOR GLYCOENGINEERING AND METHODS OF USE | PERSONS, JENNA L | 85d overdue |
| 18253576 | ACTIVE CANCER IMMUNOTHERAPY BY IMMUNE MODULATION VIA GLOBO SERIES ANTIGENS | HAM, JIEUN | 28d overdue |
| 17595830 | COMPANION DIAGNOSTIC ASSAY FOR GLOBO-H RELATED CANCER THERAPY | COUNTS, GARY W | 11d overdue |
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | SALMON, KATHERINE D | 9d |
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | NESTOR, DONNA MICHELLE | — |
| 17997490 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF COLORECTAL CANCER | SALMON, KATHERINE D | — |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | — |
| 17756022 | USE OF ANTI-EPCAM ANTIBODIES IN CANCER THERAPY | LU, CHENG | — |
| Client (Assignee) | Pending OAs |
|---|---|
| EG BIOMED CO., LTD. | 2 |
| Future Pharmtech Inc. | 1 |
| Rock BioMedical Inc. | 1 |
| China Medical University | 1 |
| OBI Pharma, Inc. | 1 |
| National Health Research Institutes | 1 |
| Mycomagic Biotechnology Co., Ltd. | 1 |
| Academia Sinica | 1 |
| Ming-Tain Lai | 1 |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 1637 | 1 |
| 1618 | 1 |
| 1643 | 1 |
| 1675 | 1 |
| 1600 | 1 |
| 1642 | 1 |
| 1678 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | Eg Biomed Co., Ltd. | SALMON, KATHERINE D | 1682 | §101§103 | Non-Final OA | 9d | Pending | Dec 11, 2024 |
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | Future Pharmtech Inc. | NESTOR, DONNA MICHELLE | §103 | Non-Final OA | — | Pending | Aug 07, 2024 | |
| 18747694 | CELLS FOR GLYCOENGINEERING AND METHODS OF USE | Rock Biomedical Inc. | PERSONS, JENNA L | 1637 | §112 | Non-Final OA | 85d overdue | Pending | Jun 19, 2024 |
| 18335897 | NANOCAPSULE AND USES THEREOF | China Medical University | BAEK, JONGHWAN NMN | 1618 | §103Other | Non-Final OA | 22d overdue | Pending | Jun 15, 2023 |
| 18253576 | ACTIVE CANCER IMMUNOTHERAPY BY IMMUNE MODULATION VIA GLOBO SERIES ANTIGENS | Obi Pharma, Inc. | HAM, JIEUN | 1643 | §102§103§112 | Non-Final OA | 28d overdue | Pending | May 18, 2023 |
| 17997490 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF COLORECTAL CANCER | Eg Biomed Co., Ltd. | SALMON, KATHERINE D | 1682 | §112 | Final Rejection | — | Pending | Oct 28, 2022 |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | National Health Research Institutes | BALLARD, KIMBERLY | 1675 | §101§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17821291 | IMMUNOMODULATORY PROTEIN FOR PREVENTION OF CORONAVIRUS INFECTION | Mycomagic Biotechnology Co., Ltd. | SPAINE, ROBERT FRANKLIN | 1600 | §112Other | Non-Final OA | — | Pending | Aug 22, 2022 |
| 17756022 | USE OF ANTI-EPCAM ANTIBODIES IN CANCER THERAPY | Academia Sinica | LU, CHENG | 1642 | §103§112Other | Non-Final OA | — | Pending | May 13, 2022 |
| 17595830 | COMPANION DIAGNOSTIC ASSAY FOR GLOBO-H RELATED CANCER THERAPY | Ming-Tain Lai | COUNTS, GARY W | 1678 | §101§103§112 | Non-Final OA | 11d overdue | Pending | Nov 24, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial